Abstract
The HIV-1 accessory protein Vpu is emerging as a viral factor with a range of activities devoted to counteracting host innate immunity. Here, we review recent findings concerning the role of Vpu in hampering activation of cellular immune responses mediated by CD1d-restricted invariant natural killer T (iNKT) cells and natural killer (NK) cells. The two key findings are that Vpu interferes with CD1d expression and antigen presentation, and also with expression of the NK cell activation ligand NK-T and B cell antigen (NTB-A). Both these activities are mechanistically distinct from CD4 and Tetherin (BST-2) down-modulation. We summarize the mechanistic insights gained into Vpu interference with CD1d and NTB-A, as well as important challenges going forward, and discuss these mechanisms in the context of the role that iNKT and NK cells play in HIV-1 immunity and immunopathogenesis
Keywords: HIV-1, iNKT cells, CD1d, Vpu, NK cells, immune evasion, NTB-A, Nef, Vpr, down-regulation
Current HIV Research
Title:HIV-1 Vpu Interference with Innate Cell-mediated Immune Mechanisms
Volume: 10 Issue: 4
Author(s): Johan K. Sandberg, Sofia K. Andersson, Susanna M. Bachle, Douglas F. Nixon and Markus Moll
Affiliation:
Keywords: HIV-1, iNKT cells, CD1d, Vpu, NK cells, immune evasion, NTB-A, Nef, Vpr, down-regulation
Abstract: The HIV-1 accessory protein Vpu is emerging as a viral factor with a range of activities devoted to counteracting host innate immunity. Here, we review recent findings concerning the role of Vpu in hampering activation of cellular immune responses mediated by CD1d-restricted invariant natural killer T (iNKT) cells and natural killer (NK) cells. The two key findings are that Vpu interferes with CD1d expression and antigen presentation, and also with expression of the NK cell activation ligand NK-T and B cell antigen (NTB-A). Both these activities are mechanistically distinct from CD4 and Tetherin (BST-2) down-modulation. We summarize the mechanistic insights gained into Vpu interference with CD1d and NTB-A, as well as important challenges going forward, and discuss these mechanisms in the context of the role that iNKT and NK cells play in HIV-1 immunity and immunopathogenesis
Export Options
About this article
Cite this article as:
K. Sandberg Johan, K. Andersson Sofia, M. Bachle Susanna, F. Nixon Douglas and Moll Markus, HIV-1 Vpu Interference with Innate Cell-mediated Immune Mechanisms, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792513
DOI https://dx.doi.org/10.2174/157016212800792513 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Recent Advances in the Biochemistry and Treatment of Cysticercosis Guest Editor: Marta C. Romano ]
Current Topics in Medicinal Chemistry Nanotechnological Systems and Lung: A Perfect Combination for Lung Pharmaceutical Applications
Current Medicinal Chemistry Mouse Models of Myasthenia Gravis
Current Pharmaceutical Design Role of Oxidative Stress and Inflammation in Insomnia Sleep Disorder and Cardiovascular Diseases: Herbal Antioxidants and Anti-inflammatory Coupled with Insomnia Detection using Machine Learning
Current Pharmaceutical Design Cytokine Therapeutics for the Treatment of Sepsis: Why has Nothing Worked?
Current Pharmaceutical Design Editorial [Hot topic: The Hypoxia-Inducible Factor (HIF) Pathway as a Target for Prevention and Treatment of Clinical Manifestations (Executive Editor: Thomas Kietzmann)]
Current Pharmaceutical Design A Role for Leptin in the Systemic Inflammatory Response Syndrome (SIRS) and in Immune Response
Current Drug Targets - Inflammation & Allergy The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry NF-κB in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Current Rheumatology Reviews Morphine as a Potential Oxidative Stress-Causing Agent
Mini-Reviews in Organic Chemistry Safety of Gene Therapy: New Insights to a Puzzling Case
Current Gene Therapy Atherosclerosis and Arterial Blood Pressure in Mice
Current Drug Targets Reducing Food Allergy: Is There Promise for Food Applications?
Current Pharmaceutical Design Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Nanoparticles of Lyotropic Liquid Crystals: A Novel Strategy for the Topical Delivery of a Chlorin Derivative for Photodynamic Therapy of Skin Cancer
Current Nanoscience Neural and Behavioral Responses to Systemic Immunologic Stimuli: A Consideration of Bacterial T Cell Superantigens
Current Pharmaceutical Design Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued)